汇宇制药：注射用HY0001a I期临床试验首例受试者给药

Core Viewpoint - Huiyu Pharmaceutical (688553.SH) announced that its wholly-owned subsidiary Sichuan Huiyu Haiyue Pharmaceutical Technology Co., Ltd. has initiated a Phase I clinical trial for its self-developed innovative biological drug injection HY0001a, aimed at treating advanced solid tumors, with the first patient successfully dosed recently [1] Group 1: Product Development - Injection HY0001a is an antibody-drug conjugate classified as a Class 1 innovative therapeutic biological product [1] - As of the announcement date, there are no approved products targeting the same site in both domestic and international markets [1] Group 2: Research and Efficacy - Research indicates that CDCP1 is highly expressed in various tumors such as gastric cancer, breast cancer, lung cancer, colorectal cancer, and pancreatic cancer, while normal tissues show low or no expression, making it a significant potential target for ADC drug development [1] - Preclinical studies demonstrate that HY0001a exhibits excellent anti-tumor effects and good safety in multiple solid tumor models, indicating substantial clinical development value [1]